Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Impedimed Limited ( (AU:IPD) ) just unveiled an update.
ImpediMed Limited announced a change in the director’s interest, with Mr. Andrew Grant acquiring 268,169 ordinary shares, increasing his total to 2,774,399 shares. This acquisition was made through the issuance of shares in lieu of 30% of director fees for the quarter ended June 30, 2025, reflecting a strategic decision to align director compensation with company performance.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, focusing on the development and distribution of non-invasive medical devices. The company specializes in bioimpedance spectroscopy, which is used for the clinical assessment of fluid status and tissue composition.
Average Trading Volume: 2,702,662
Technical Sentiment Signal: Sell
Current Market Cap: A$103.4M
See more data about IPD stock on TipRanks’ Stock Analysis page.